Early changes in auditory function as a result of platinum chemotherapy: Use of extended high-frequency audiometry and evoked distortion product otoacoustic emissions

Journal of Clinical Oncology

Volumn 25, Issue 10, 2007, Pages 1190-1195

  Knight, Kristin R ^b   Kraemer, Dale P ^b   Winter, Christiane ^b   Neuwelt, Edward A ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; PLATINUM COMPLEX; ANTINEOPLASTIC AGENT;

ADOLESCENT; ADULT; ARTICLE; AUDIOLOGY; AUDIOMETRY; CANCER; CANCER CHEMOTHERAPY; CHILD; CLINICAL ARTICLE; COCHLEA; CONTROLLED STUDY; CORRELATION ANALYSIS; DISTORTION PRODUCT OTOACOUSTIC EMISSION; DRUG MEGADOSE; EVOKED AUDITORY RESPONSE; FEASIBILITY STUDY; FEMALE; HEARING; HEARING LOSS; HUMAN; INFANT; MALE; OTOTOXICITY; PRIORITY JOURNAL; SCORING SYSTEM; SIDE EFFECT; DRUG EFFECT; METHODOLOGY; PRESCHOOL CHILD; SPONTANEOUS OTOACOUSTIC EMISSION;

ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS; AUDIOMETRY; CARBOPLATIN; CHILD; CHILD, PRESCHOOL; CISPLATIN; FEMALE; HEARING; HUMANS; INFANT; MALE; OTOACOUSTIC EMISSIONS, SPONTANEOUS;

EID: 34247110863     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2006.07.9723     Document Type: Article

References (22)

1. Li Y, Womer RB, Silber JH: Predicting cisplatin ototoxicity in children: The influence of age and the cumulative dose. Eur J Cancer: 40:2445-2451, 2004
2. Montaguti M, Brandolini C, Ferri GG, et al: Cisplatin and carboplatin-induced ototoxicity in children: Clinical aspects and perspectives for prevention. Acta Otorhinolaryngol Ital 22:14-18, 2002
3. Macdonald RM, Harrison RV, Wake M, et al: Ototoxicity of carboplatin: Comparing animal and clinical models at the Hospital for Sick Children. J Otolaryngo 123:151-159, 1994
4. Parsons SK, Neault MW, Lehmann LE, et al: Severe ototoxicity following carboplatin-containing conditioning regimen for autologous marrow transplantation for neuroblastoma. Bone Marrow Transplant 22:669-674, 1998
5. Bertolini P, Lassalle M, Guilaine M, et al: Platinum compound-related ototoxicity in children: Long-term follow-up reveals continuous worsening of hearing loss. Pediatr Hematol Oncol 26:649-655, 2004
6. Brock PR, Bellman SC, Yeomans EC, et al: Cisplatin ototoxicity in children: A practical grading system. Med Pediatr Oncol 19:295-300, 1991
7. Lanvers-Kaminsky C, Krefeld B, Dinnesen AG, et al: Continuous or repeated prolonged cisplatin infusions in children: A prospective study on ototoxicity, platinum concentrations, and standard serum parameters. Pediatric Blood and Cancer 47:183-193, 2006
8. Campbell K: Ototoxicity: Understanding oxidative mechanisms. J Am Acad Audiol 14:121-123, 2003
9. Lonsbury-Martin BL, Martin GK: Evoked otoacoustic emissions as objective screeners for ototoxicity. Seminars in Hearing 22:377-391, 2001
10. Fausti SA, Larson VD, Noffsinger D, et al: High frequency audiometric monitoring strategies for early detection of ototoxicity. Ear Hear 15:232-239, 1994
11. Ress BD, Sridhar KS, Balkany TJ, et al: Effects of cis-platinum chemotherapy on otoacoustic emissions: The development of an objective screening protocol. Otolaryngology - Head and Neck Surgery 121:693-701, 1999
12. Littman TA, Magruder A, Strother DR: Monitoring and predicting ototoxic damage using distortion-product otoacoustic emissions: Pediatric case study. J Am Acad Audiol 9:257-262, 1998
13. Wright CG, Schaefer SD: Inner ear histopathology in patients treated with cisplatin. Laryngoscope 92:1408-1413, 1982
14. Gorga MP, Neely ST, Bergman B, et al: Otoacoustic emissions from normal-hearing and hearing-impaired subjects: Distortion product responses. J Acoust Soc Am 93:2050-2060, 1993
15. Rybak LP, Whitworth CA: Ototoxicity: Therapeutic opportunities. Drug Discovery Today 10: 1313-1321, 2005
16. Leigh-Paffenroth E, Reavis KM, Gordon JS, et al: Objective measures of ototoxicity. ASHA Special Interest Division 6, Hearing and Hearing Disorders: Research and Diagnostics 9:10-16, 2005
17. Franklin DJ, McCoy MJ, Martin GK, et al: Test/retest reliability of distortion product and transiently evoked otoacoustic emissions. Ear Hear 15: 232-239, 1992
18. Shehata-Dieler WE, Dieler R, Teichert K, et al: Intra- and intersubject variability of acoustically evoked otoacoustic emissions II. Distortion product otoacoustic emissions. Laryngorhinootologie 78: 345-350, 1999
19. Beattie RC, Kenworthy OT, Luna CA: Immediate and short-term reliability of distortion-product otoacoustic emissions. International Journal of Audiology 42:348-354, 2003
20. American Speech-Language-Hearing Association: Guidelines for the audiologic management of individuals receiving cochleotoxic drug therapy. ASHA 36:11-19, 1994 (suppl 12)
21. National Cancer Institute: Common Terminology Criteria for Adverse Events, version 3.0, 2006. http://ctep.cancer.gov/forms/CTCAEv3.pdf
22. Blakley BW, Cohen JI, Doolittle ND, et al: Strategies for prevention of toxicity caused by platinum-based chemotherapy: Review and summary of the annual meeting of the blood-brain barrier disruption program, Gleneden Beach, Oregon, March 10, 2001. Laryngoscope, 112: 1997-2001, 2002